|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CWC15 |
Gene summary for CWC15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CWC15 | Gene ID | 51503 |
| Gene name | CWC15 spliceosome associated protein homolog | |
| Gene Alias | AD002 | |
| Cytomap | 11q21 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9P013 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51503 | CWC15 | LZE2T | Human | Esophagus | ESCC | 1.75e-06 | 8.66e-01 | 0.082 |
| 51503 | CWC15 | LZE4T | Human | Esophagus | ESCC | 3.37e-17 | 3.20e-01 | 0.0811 |
| 51503 | CWC15 | LZE7T | Human | Esophagus | ESCC | 1.76e-03 | 2.57e-01 | 0.0667 |
| 51503 | CWC15 | LZE8T | Human | Esophagus | ESCC | 3.65e-22 | 2.19e-01 | 0.067 |
| 51503 | CWC15 | LZE20T | Human | Esophagus | ESCC | 2.05e-07 | 2.83e-01 | 0.0662 |
| 51503 | CWC15 | LZE22T | Human | Esophagus | ESCC | 9.11e-04 | 1.55e-01 | 0.068 |
| 51503 | CWC15 | LZE24T | Human | Esophagus | ESCC | 2.80e-28 | 7.26e-01 | 0.0596 |
| 51503 | CWC15 | LZE21T | Human | Esophagus | ESCC | 1.06e-04 | 2.75e-01 | 0.0655 |
| 51503 | CWC15 | LZE6T | Human | Esophagus | ESCC | 1.54e-12 | 2.17e-01 | 0.0845 |
| 51503 | CWC15 | P1T-E | Human | Esophagus | ESCC | 2.32e-15 | 4.63e-01 | 0.0875 |
| 51503 | CWC15 | P2T-E | Human | Esophagus | ESCC | 8.98e-21 | 3.85e-01 | 0.1177 |
| 51503 | CWC15 | P4T-E | Human | Esophagus | ESCC | 9.26e-47 | 1.23e+00 | 0.1323 |
| 51503 | CWC15 | P5T-E | Human | Esophagus | ESCC | 3.49e-55 | 1.06e+00 | 0.1327 |
| 51503 | CWC15 | P8T-E | Human | Esophagus | ESCC | 1.52e-49 | 1.16e+00 | 0.0889 |
| 51503 | CWC15 | P9T-E | Human | Esophagus | ESCC | 2.00e-35 | 6.93e-01 | 0.1131 |
| 51503 | CWC15 | P10T-E | Human | Esophagus | ESCC | 1.30e-33 | 6.45e-01 | 0.116 |
| 51503 | CWC15 | P11T-E | Human | Esophagus | ESCC | 1.67e-23 | 9.05e-01 | 0.1426 |
| 51503 | CWC15 | P12T-E | Human | Esophagus | ESCC | 3.60e-41 | 7.47e-01 | 0.1122 |
| 51503 | CWC15 | P15T-E | Human | Esophagus | ESCC | 1.18e-28 | 3.74e-01 | 0.1149 |
| 51503 | CWC15 | P16T-E | Human | Esophagus | ESCC | 2.68e-34 | 7.24e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
| GO:000037517 | Prostate | BPH | RNA splicing, via transesterification reactions | 114/3107 | 324/18723 | 2.19e-16 | 4.53e-14 | 114 |
| GO:000037717 | Prostate | BPH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
| GO:000039817 | Prostate | BPH | mRNA splicing, via spliceosome | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
| GO:000838019 | Prostate | Tumor | RNA splicing | 153/3246 | 434/18723 | 9.15e-20 | 5.79e-17 | 153 |
| GO:000037518 | Prostate | Tumor | RNA splicing, via transesterification reactions | 119/3246 | 324/18723 | 3.40e-17 | 1.06e-14 | 119 |
| GO:000037718 | Prostate | Tumor | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
| GO:000039818 | Prostate | Tumor | mRNA splicing, via spliceosome | 117/3246 | 320/18723 | 9.31e-17 | 2.22e-14 | 117 |
| GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
| GO:0000375112 | Skin | cSCC | RNA splicing, via transesterification reactions | 201/4864 | 324/18723 | 4.07e-43 | 5.10e-40 | 201 |
| GO:0000377112 | Skin | cSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| GO:0000398112 | Skin | cSCC | mRNA splicing, via spliceosome | 197/4864 | 320/18723 | 1.45e-41 | 1.14e-38 | 197 |
| GO:0008380113 | Thyroid | PTC | RNA splicing | 273/5968 | 434/18723 | 4.44e-41 | 1.40e-37 | 273 |
| GO:0000375113 | Thyroid | PTC | RNA splicing, via transesterification reactions | 202/5968 | 324/18723 | 6.81e-30 | 3.91e-27 | 202 |
| GO:0000377113 | Thyroid | PTC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:0000398113 | Thyroid | PTC | mRNA splicing, via spliceosome | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
| GO:000838034 | Thyroid | ATC | RNA splicing | 270/6293 | 434/18723 | 7.50e-35 | 1.19e-31 | 270 |
| GO:000037534 | Thyroid | ATC | RNA splicing, via transesterification reactions | 200/6293 | 324/18723 | 1.75e-25 | 7.39e-23 | 200 |
| GO:000037734 | Thyroid | ATC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
| GO:000039834 | Thyroid | ATC | mRNA splicing, via spliceosome | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304010 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
| hsa0304015 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
| hsa0304025 | Prostate | Tumor | Spliceosome | 66/1791 | 217/8465 | 7.53e-04 | 3.59e-03 | 2.23e-03 | 66 |
| hsa0304035 | Prostate | Tumor | Spliceosome | 66/1791 | 217/8465 | 7.53e-04 | 3.59e-03 | 2.23e-03 | 66 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CWC15 | SNV | Missense_Mutation | novel | c.72C>A | p.Ser24Arg | p.S24R | Q9P013 | protein_coding | tolerated(0.08) | benign(0.195) | TCGA-B6-A408-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| CWC15 | SNV | Missense_Mutation | novel | c.424N>C | p.Glu142Gln | p.E142Q | Q9P013 | protein_coding | tolerated(0.26) | probably_damaging(0.992) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| CWC15 | SNV | Missense_Mutation | novel | c.69G>C | p.Leu23Phe | p.L23F | Q9P013 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| CWC15 | SNV | Missense_Mutation | rs782295901 | c.163C>T | p.Arg55Cys | p.R55C | Q9P013 | protein_coding | tolerated(0.11) | benign(0.005) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CWC15 | SNV | Missense_Mutation | novel | c.388C>G | p.Leu130Val | p.L130V | Q9P013 | protein_coding | tolerated(0.05) | benign(0.148) | TCGA-AF-2690-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CWC15 | insertion | Frame_Shift_Ins | novel | c.275_276insA | p.Pro93AlafsTer12 | p.P93Afs*12 | Q9P013 | protein_coding | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
| CWC15 | SNV | Missense_Mutation | novel | c.140N>A | p.Thr47Asn | p.T47N | Q9P013 | protein_coding | deleterious(0.02) | possibly_damaging(0.562) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CWC15 | SNV | Missense_Mutation | novel | c.433N>C | p.Ala145Pro | p.A145P | Q9P013 | protein_coding | tolerated(0.09) | possibly_damaging(0.521) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CWC15 | SNV | Missense_Mutation | novel | c.323C>A | p.Pro108His | p.P108H | Q9P013 | protein_coding | deleterious(0.04) | possibly_damaging(0.888) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CWC15 | SNV | Missense_Mutation | novel | c.232N>T | p.Arg78Cys | p.R78C | Q9P013 | protein_coding | deleterious(0.04) | possibly_damaging(0.83) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |